VOYA Investment Management’s Galectin Therapeutics GALT Stock Holding History

VOYA Investment Management’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-18,928	Closed	-$41K	–	2843
2021 Q1	$41K	Hold	18,928	–	–	﹤0.01%	2753
2020 Q4	$42K	Buy	18,928 +5,309	+39%	+$13.9K	﹤0.01%	2668
2020 Q3	$36K	Hold	13,619	–	–	﹤0.01%	2468
2020 Q2	$42K	Sell	13,619 -9,355	-41%	-$23.5K	﹤0.01%	2462
2020 Q1	$45K	Hold	22,974	–	–	﹤0.01%	2507
2019 Q4	$66K	Buy	22,974 +7,797	+51%	+$27.1K	﹤0.01%	2615
2019 Q3	$56K	Hold	15,177	–	–	﹤0.01%	2489
2019 Q2	$63K	Buy	+15,177	New	+$65.7K	﹤0.01%	2541
2015 Q2	–	Sell	-13,649	Closed	-$46K	–	2646
2015 Q1	$46K	Hold	13,649	–	–	﹤0.01%	2553
2014 Q4	$47K	Hold	13,649	–	–	﹤0.01%	2592
2014 Q3	$69K	Hold	13,649	–	–	﹤0.01%	2602
2014 Q2	$188K	Buy	+13,649	New	+$170K	﹤0.01%	2581

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management's GALT Position: Q2 2021 in Review

VOYA Investment Management sold out of Galectin Therapeutics (GALT) in Q2 2021, closing a stake of 18,928 shares — an estimated $41K sold.

VOYA Investment Management first reported a position in GALT in Q2 2014 and held it in 12 quarters. The position peaked at $188K in Q2 2014. 75 funds tracked by Wall St. Rank hold GALT as of Q2 2021.

VOYA Investment Management reported no remaining Galectin Therapeutics position as of Q2 2021 after selling out during the quarter.
VOYA Investment Management sold 18,928 Galectin Therapeutics shares in Q2 2021, an estimated $41K.
VOYA Investment Management first reported a position in Galectin Therapeutics in Q2 2014 and held it in 12 quarters.
VOYA Investment Management's Galectin Therapeutics position peaked at $188K in Q2 2014.
75 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2021.

Based on VOYA Investment Management's 13F filing for Q2 2021, filed 16 Aug 2021.